- Main
Comprehensive characterization of the cancer microbiome and its immuno-oncology interface
- Poore, Gregory Derrick
- Advisor(s): Knight, Rob;
- Hasty, Jeff
Abstract
By all measures of genetic diversity or species abundance, life is primarily microbial. However, decades of cancer genomics have treated human tumors as sterile entities. The central argument of this thesis is that this sterility assumption is unfounded, unnecessary, and harmful for the future of cancer care. In Chapter 1, I comprehensively outline the literature landscape of cancer-associated microbes and their impact on each stage of the clinical cancer care cycle. I demonstrate that the majority of known cancer “hallmarks” are impacted by microbial mechanisms that act proximal and distal to tumors. I further summarize microbial impacts on cancer into an “immuno-oncology-microbiome” (IOM) axis and critically review the landscape of intratumoral and intracellular bacteria. In Chapter 2, I then argue (i) how microbiome-augmented cancer diagnostics directly benefit from the microbiome’s diversity and (ii) how the intratumoral microbiome necessitates a redefinition of cancer clonal evolution as a multi-species process. Evaluating multi-species clonal evolution, in turn, impacts how the field should model therapeutic resistance and metastasis. In Chapter 3, I present the largest to-date analysis of microbes in cancer, covering ~18,000 samples across 33 cancer types and more than 10,000 patients. Critically, I find microbial DNA and RNA is present in every major human cancer. I further show that these microbial compositions are cancer type-specific and that a patient’s cancer type is predictable solely on the basis of microbial nucleic acids found in cancer tissues, whole blood, or plasma, thereby concluding that microbial nucleic acids comprise a novel class of cancer diagnostics. In Chapter 4, I explore fungal constituents of the cancer microbiome, finding fungal DNA and RNA across most types of human cancers, and demonstrate that these fungal ecologies are also cancer type-specific. I also characterize fungal-bacterial-immune co-occurrences, revealing distinct immune responses, associations with patient survival, and multi-domain intratumoral ecologies. Collectively, these chapters and analyses comprehensively characterize the existence of the cancer microbiome, its immuno-oncology interface, and its utility for improving cancer diagnostics, prognostics, and therapeutics.